🚀 VC round data is live in beta, check it out!
Alkem Laboratories Valuation Multiples
Discover revenue and EBITDA valuation multiples for Alkem Laboratories and similar public comparables like Arcellx, Belite Bio, China Resources Sanjiu, Bachem and more.
Alkem Laboratories Overview
About Alkem Laboratories
Alkem Laboratories Ltd is an Indian pharmaceutical company engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals in acute and chronic therapeutic areas, such as anti-infective, pain and analgesics, vitamins/minerals/nutrients, cardiac and Diabetology, Gynecology, neuro/central nervous system, dermatology, anti-diabetes, anti-osteoporosis, cardiovascular, and muscle relaxants, which are marketed in Indian and International markets. It operates through the pharmaceutical business segment.
Founded
1973
HQ
Employees
18.6K
Website
Sectors
Financials (LTM)
EV
$6B
Alkem Laboratories Financials
Alkem Laboratories reported last 12-month revenue of $2B and EBITDA of $325M.
In the same LTM period, Alkem Laboratories generated $1B in gross profit, $325M in EBITDA, and $269M in net income.
Revenue (LTM)
Alkem Laboratories P&L
In the most recent fiscal year, Alkem Laboratories reported revenue of $2B and EBITDA of $314M.
Alkem Laboratories expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2B | XXX | $2B | XXX | XXX | XXX |
| Gross Profit | $1B | XXX | $841M | XXX | XXX | XXX |
| Gross Margin | 65% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | $325M | XXX | $314M | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBIT Margin | 18% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $269M | XXX | $253M | XXX | XXX | XXX |
| Net Margin | 17% | XXX | 17% | XXX | XXX | XXX |
| Net Debt | — | — | $80M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Alkem Laboratories Stock Performance
Alkem Laboratories has current market cap of $7B, and enterprise value of $6B.
Market Cap Evolution
Alkem Laboratories' stock price is $56.76.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $6B | $7B | -2.9% | XXX | XXX | XXX | $2.12 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialAlkem Laboratories Valuation Multiples
Alkem Laboratories trades at 4.1x EV/Revenue multiple, and 20.0x EV/EBITDA.
EV / Revenue (LTM)
Alkem Laboratories Financial Valuation Multiples
As of April 14, 2026, Alkem Laboratories has market cap of $7B and EV of $6B.
Equity research analysts estimate Alkem Laboratories' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Alkem Laboratories has a P/E ratio of 25.2x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7B | XXX | $7B | XXX | XXX | XXX |
| EV (current) | $6B | XXX | $6B | XXX | XXX | XXX |
| EV/Revenue | 4.1x | XXX | 4.3x | XXX | XXX | XXX |
| EV/EBITDA | 20.0x | XXX | 20.6x | XXX | XXX | XXX |
| EV/EBIT | 22.4x | XXX | 25.0x | XXX | XXX | XXX |
| EV/Gross Profit | 6.4x | XXX | 7.7x | XXX | XXX | XXX |
| P/E | 25.2x | XXX | 26.8x | XXX | XXX | XXX |
| EV/FCF | 37.2x | XXX | 38.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Alkem Laboratories Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Alkem Laboratories Margins & Growth Rates
Alkem Laboratories' revenue in the last 12 month grew by 11%.
Alkem Laboratories' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.0M for the same period.
Alkem Laboratories' rule of 40 is 33% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Alkem Laboratories' rule of X is 52% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Alkem Laboratories Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 11% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 21% | XXX | 21% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 3% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 33% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 52% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 9% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 40% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Alkem Laboratories Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Alkem Laboratories | XXX | XXX | XXX | XXX | XXX | XXX |
| Arcellx | XXX | XXX | XXX | XXX | XXX | XXX |
| Belite Bio | XXX | XXX | XXX | XXX | XXX | XXX |
| China Resources Sanjiu | XXX | XXX | XXX | XXX | XXX | XXX |
| Bachem | XXX | XXX | XXX | XXX | XXX | XXX |
| Glenmark Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkem Laboratories M&A Activity
Alkem Laboratories acquired XXX companies to date.
Last acquisition by Alkem Laboratories was on XXXXXXXX, XXXXX. Alkem Laboratories acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Alkem Laboratories
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialAlkem Laboratories Investment Activity
Alkem Laboratories invested in XXX companies to date.
Alkem Laboratories made its latest investment on XXXXXXXX, XXXXX. Alkem Laboratories invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Alkem Laboratories
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Alkem Laboratories
| When was Alkem Laboratories founded? | Alkem Laboratories was founded in 1973. |
| Where is Alkem Laboratories headquartered? | Alkem Laboratories is headquartered in India. |
| How many employees does Alkem Laboratories have? | As of today, Alkem Laboratories has over 18K employees. |
| Is Alkem Laboratories publicly listed? | Yes, Alkem Laboratories is a public company listed on National Stock Exchange of India. |
| What is the stock symbol of Alkem Laboratories? | Alkem Laboratories trades under ALKEM ticker. |
| When did Alkem Laboratories go public? | Alkem Laboratories went public in 2015. |
| Who are competitors of Alkem Laboratories? | Alkem Laboratories main competitors are Arcellx, Belite Bio, China Resources Sanjiu, Bachem. |
| What is the current market cap of Alkem Laboratories? | Alkem Laboratories' current market cap is $7B. |
| What is the current revenue of Alkem Laboratories? | Alkem Laboratories' last 12 months revenue is $2B. |
| What is the current revenue growth of Alkem Laboratories? | Alkem Laboratories revenue growth (NTM/LTM) is 11%. |
| What is the current EV/Revenue multiple of Alkem Laboratories? | Current revenue multiple of Alkem Laboratories is 4.1x. |
| Is Alkem Laboratories profitable? | Yes, Alkem Laboratories is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Alkem Laboratories? | Alkem Laboratories' last 12 months EBITDA is $325M. |
| What is Alkem Laboratories' EBITDA margin? | Alkem Laboratories' last 12 months EBITDA margin is 21%. |
| What is the current EV/EBITDA multiple of Alkem Laboratories? | Current EBITDA multiple of Alkem Laboratories is 20.0x. |
| What is the current FCF of Alkem Laboratories? | Alkem Laboratories' last 12 months FCF is $175M. |
| What is Alkem Laboratories' FCF margin? | Alkem Laboratories' last 12 months FCF margin is 11%. |
| What is the current EV/FCF multiple of Alkem Laboratories? | Current FCF multiple of Alkem Laboratories is 37.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.